On the Application of Joint-Domain Dictionary Mapping for Multiple Power Disturbance Assessment

This paper proposes a joint-domain dictionary mapping method to obtain high assessment accuracy of multiple power disturbances. Firstly, in order to achieve resolutions in both the time and frequency domains, a joint-domain dictionary is proposed which consists of a discrete Hartley base and an identity matrix. Due to the low correlation between the discrete Hartley base and the identity matrix, the joint-domain dictionary mapping can separately capture the approximations of the sinusoidal components and transients. Since the mapping coefficients contain the physical quantities, the eigenvalues of each component can be effectively estimated. A quantified eigenvalue classifier was designed for identifying power disturbances using the estimated eigenvalues. The proposed method was compared with several advanced methods through simulated power disturbances under different noise conditions, and actual data from the Institute of Electrical and Electronics Engineers Power and Energy Society database. The results reveal that the joint-domain dictionary mapping technique shows good performance on parameter estimation and recognition precision, even dealing with complicated multiple power disturbances

Active power decoupling and controlling for single-phase FACTS device

Single-phase FACTS device has a bulky and short-life electrolytic capacitor to absorb the ripple pulsating at twice of the line frequency in DC side, resulting in lower power density. This paper introduced a structure of three-phase bridge which added an additional leg connected to an AC capacitor based on single-phase H-bridge. The 2-ripple energy of the electrolytic capacitor in single-phase H-bridge could be transformed to the film capacitor of the AC side in three-phase H bridge. The size of single-phase FACTS is reduced by ten times compared to the single-phase H-bridge. A simple control strategy had been studied, through two kinds of controllers: the digital quais-PR controller had been used to control gird current and AC capacitor voltage and current; the two cosine controller had been used to eliminate the rest of two-ripple harmonic in the DC side, there was no controller to maintain DC voltage. The experiments verified the feasibility of the control strategy

KAP1 Positively Modulates Influenza A Virus Replication by Interacting with PB2 and NS1 Proteins in Human Lung Epithelial Cells

Influenza virus only encodes a dozen of viral proteins, which need to use host machinery to complete the viral life cycle. Previously, KAP1 was identified as one host protein that potentially interacts with influenza viral proteins in HEK 293 cells. However, the role of KAP1 in influenza virus replication in human lung alveolar epithelial cells and the underlying mechanism remains unclear. In this study, we first generated KAP1 KO A549 cells by CRISPR/Cas9 gene editing. KAP1 deletion had no significant effect on the cell viability and lack of KAP1 expression significantly reduced the influenza A virus replication. Moreover, we demonstrated that KAP1 is involved in the influenza virus entry, transcription/replication of viral genome, and viral protein synthesis in human lung epithelial cells and confirmed that KAP1 interacted with PB2 and NS1 viral proteins during the virus infection. Further study showed that KAP1 inhibited the production of type I IFN and overexpression of KAP1 significantly reduced the IFN-β production. In addition, influenza virus infection induces the deSUMOylation and enhanced phosphorylation of KAP1. Our results suggested that KAP1 is required for the replication of influenza A virus and mediates the replication of influenza A virus by facilitating viral infectivity and synthesis of viral proteins, enhancing viral polymerase activity, and inhibiting the type I IFN production

KAP1 Positively Modulates Influenza A Virus Replication by Interacting with PB2 and NS1 Proteins in Human Lung Epithelial Cells

Influenza virus only encodes a dozen of viral proteins, which need to use host machinery to complete the viral life cycle. Previously, KAP1 was identified as one host protein that potentially interacts with influenza viral proteins in HEK 293 cells. However, the role of KAP1 in influenza virus replication in human lung alveolar epithelial cells and the underlying mechanism remains unclear. In this study, we first generated KAP1 KO A549 cells by CRISPR/Cas9 gene editing. KAP1 deletion had no significant effect on the cell viability and lack of KAP1 expression significantly reduced the influenza A virus replication. Moreover, we demonstrated that KAP1 is involved in the influenza virus entry, transcription/replication of viral genome, and viral protein synthesis in human lung epithelial cells and confirmed that KAP1 interacted with PB2 and NS1 viral proteins during the virus infection. Further study showed that KAP1 inhibited the production of type I IFN and overexpression of KAP1 significantly reduced the IFN-β production. In addition, influenza virus infection induces the deSUMOylation and enhanced phosphorylation of KAP1. Our results suggested that KAP1 is required for the replication of influenza A virus and mediates the replication of influenza A virus by facilitating viral infectivity and synthesis of viral proteins, enhancing viral polymerase activity, and inhibiting the type I IFN production

A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine

Influenza virus infects the host and transmits through the respiratory tract (i.e., the mouth and nose); therefore, the development of intranasal influenza vaccines that mimic the natural infection, coupled with an efficient mucosal adjuvant, is an attractive alternative to current parenteral vaccines. However, with the withdrawal of cholera toxin and Escherichia coli heat-labile endotoxin from clinical use due to side effects, there are no approved adjuvants for intranasal vaccines. Therefore, safe and effective mucosal adjuvants are urgently needed. Previously, we reported that one derivative of α-Galactosylceramide (α-GalCer), 7DW8-5, could enhance the protective efficacy of split influenza vaccine by injection administration. However, the mucosal adjuvanticity of 7DW8-5 is still unclear. In this study, we found that 7DW8-5 promotes the production of secret IgA antibodies and IgG antibodies and enhances the protective efficacy of the split influenza vaccine by intranasal administration. Furthermore, co-administration of 7DW8-5 with the split influenza vaccine significantly reduces the virus shedding in the upper and lower respiratory tract after lethal challenge. Our results demonstrate that 7DW8-5 is a novel mucosal adjuvant for the split influenza vaccine